Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 2/2018

01-02-2018 | Brief Report

An influenza A virus vaccine based on an M2e-modified alphavirus

Authors: Haritha Ramya Krishnavajhala, Jacqueline Williams, Hans Heidner

Published in: Archives of Virology | Issue 2/2018

Login to get access

Abstract

The 23-residue external domain of the influenza A virus M2 protein (M2e) has significant potential as a vaccine antigen. Here, we describe the construction and characterization of an M2e-modified Sindbis virus designated E2S1-M2e. E2S1-M2e virions contain M2e as an N-terminal extension of the E2 glycoprotein and therefore express 240 copies of the M2e peptide on their surface. The E2S1-M2e virus expressed M2e in an accessible and immunogenic form and induced M2e-specific antibodies when administered to mice. Mice that received an intranasal vaccination with E2S1-M2e were protected against a lethal challenge with a virulent, mouse-adapted strain of influenza A virus.
Literature
1.
Boehme KW, Williams JC, Johnston RE, Heidner HW (2000) Linkage of an alphavirus host range restriction to the carbohydrate-processing phenotypes of the host cell. J Gen Virol 81:161–170CrossRefPubMed
2.
Feng JQ, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, Couch RB, Gerhard W (2006) Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3:1–13CrossRef
3.
Heidner HW, Johnston RE (1994) The amino-terminal residue of Sindbis virus glycoprotein E2 influences virus maturation, specific infectivity for BHK cells, and virulence in mice. J Virol 68:8064–8070PubMedPubMedCentral
4.
Heidner HW, McKnight KL, Davis NL, Johnston RE (1994) Lethality of PE2 incorporation into Sindbis virus can be suppressed by second-site mutations in E3 and E2. J Virol 68:2683–2692PubMedPubMedCentral
5.
6.
Holsinger LJ, Lamb RA (1991) Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 183:32–43CrossRefPubMed
7.
Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG (1991) Evolutionary analysis of the influenza A virus M gene with comparisons of the M1 and M2 proteins. J Virol 65:5491–5498PubMedPubMedCentral
8.
Klimstra WB, Williams JC, Ryman KD, Heidner HW (2005) Targeting Sindbis virus-based vectors to Fc receptor-positive cell types. Virology 338:9–21CrossRefPubMed
9.
Kolpe A, Schepens B, Fiers W, Saelens X (2016) M2-based influenza vaccines: recent advances and clinical potential. Expert Rev Vaccines 16:123–136CrossRefPubMed
10.
Krammer F, Palese P (2015) Advances in the development of influenza virus vaccines. Nat Rev 14:167–182
11.
Lamb RA, Zebedee SL, Richardson CD (1985) Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40:627–633CrossRefPubMed
12.
13.
Luytjes W, Enouf V, Schipper M, Gijzen K, Liu WM, van der Lubben M, Meijer A, van der Werf S, Soethout EC (2012) HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains. Vaccine 30:5262–5269CrossRefPubMed
14.
Mukhopadhyay S, Zhang W, Gabler S, Chipman PR, Strauss EG, Strauss JH, Baker TS, Kuhn RJ, Rossmann MG (2006) Mapping the structure and function of the E1 and E2 glycoproteins in alphaviruses. Structure 14:63–73CrossRefPubMedPubMedCentral
15.
Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157–1163CrossRefPubMed
16.
17.
Paredes AM, Brown DT, Rothnagel R, Chiu W, Schoepp RJ, Johnston RE (1993) Three-dimensional structure of a membrane-containing virus. Proc Natl Acad Sci USA 90:9095–9099CrossRefPubMedPubMedCentral
18.
Paredes AM, Heidner H, Thuman-Commike P, Prasad BVV, Johnston RE, Chiu W (1998) Structural localization of the E3 glycoprotein in attenuated Sindbis virus mutants. J Virol 72:1534–1541PubMedPubMedCentral
19.
Pinto LH, Holsinger LJ, Lamb RA (1992) Influenza virus M2 protein has ion channel activity. Cell 69:517–528CrossRefPubMed
20.
Reid AH, Fanning TG, Janczewski TA, McCall S, Taubenberger JK (2002) Characterization of the 1918 “Spanish” influenza virus matrix gene segment. J Virol 76:10717–10723CrossRefPubMedPubMedCentral
21.
Rice CM, Strauss JH (1982) Association of Sindbis virion glycoproteins and their precursors. J Mol Biol 154:325–348CrossRefPubMed
22.
Ryman KD, Klimstsra WB, Nguyen KB, Biron CA, Johnston RE (2000) Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J Virol 74:3366–3378CrossRefPubMedPubMedCentral
23.
Sakaguchi T, Leser GP, Lamb RA (1996) The ion channel activity of the influenza virus M2 protein affects transport through the Golgi apparatus. J Cell Biol 133:733–747CrossRefPubMed
24.
Schmaljohn AL, Johnson ED, Dalrymple JM, Cole GA (1982) Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 297:70–72CrossRefPubMed
25.
26.
Stouffer AL, Acharya R, Salom D, Levine AS, DiCostanzo L, Soto CS, Tereshko V, Nanda V, Stayrook S, DeGrado WF (2008) Structural basis for the function and inhibition of an influenza virus proton channel. Nature 451:596–599CrossRefPubMed
27.
Sugrue RJ, Hay AJ (1991) Structural characteristics of the M2 protein of influenza A virus: evidence that it forms a tetrameric channel. Virology 180:617–624CrossRefPubMed
28.
Takeuchi K, Lamb RA (1994) Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plaque virus hemagglutinin during intracellular transport. J Virol 68:911–919PubMedPubMedCentral
29.
Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA et al (2012) A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci USA 109:4269–4274CrossRefPubMedPubMedCentral
30.
Von Bonsdorff CH, Harrison SC (1975) Sindbis virus glycoproteins form a regular icosahedral lattice. J Virol 16:141–145
31.
Whetter LE, MacLachlan NJ, Gebhard DH, Heidner HW, Moore PF (1989) Bluetongue virus infection of bovine monocytes. J Gen Virol 70:1663–1676CrossRefPubMed
32.
Zebedee SL, Lamb RA (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62:2762–2772PubMedPubMedCentral
Metadata
Title
An influenza A virus vaccine based on an M2e-modified alphavirus
Authors
Haritha Ramya Krishnavajhala
Jacqueline Williams
Hans Heidner
Publication date
01-02-2018
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 2/2018
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-017-3578-8

Other articles of this Issue 2/2018

Archives of Virology 2/2018 Go to the issue

Brief Report

Impact of IL-10-1082A/G gene polymorphism on the severity of EV71 infection in Chinese children

Brief Report

First detection of Nebovirus and Norovirus from cattle in China

Rapid Communication

Feline immudeficiency virus subtypes B and A in cats from São Luis, Maranhão, Brazil

Original Article

Early HIV infection among persons referred for malaria parasite testing in Nigeria

Annotated Sequence Record

Characterization of a novel RNA virus from Nesidiocoris tenuis related to members of the genus Iflavirus

Original Article

Evidence of infection with avian, human, and swine influenza viruses in pigs in Cairo, Egypt
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits